Alec Stranahan
Stock Analyst at B of A Securities
(0.80)
# 4,039
Out of 5,118 analysts
32
Total ratings
40%
Success rate
-25.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $182 → $255 | $247.88 | +2.87% | 5 | Oct 17, 2025 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $5.71 | +22.59% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $15.03 | -20.16% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $3.54 | -71.71% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $6.72 | +4.17% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $27.82 | +50.97% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $9.18 | +172.33% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.59 | +591.82% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $2.74 | +118.98% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.04 | +637.10% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $79.54 | -30.85% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $29.75 | -79.83% | 2 | Dec 29, 2022 |
Krystal Biotech
Oct 17, 2025
Maintains: Buy
Price Target: $182 → $255
Current: $247.88
Upside: +2.87%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $5.71
Upside: +22.59%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $15.03
Upside: -20.16%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $3.54
Upside: -71.71%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $6.72
Upside: +4.17%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $27.82
Upside: +50.97%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $9.18
Upside: +172.33%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.59
Upside: +591.82%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $2.74
Upside: +118.98%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.04
Upside: +637.10%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $79.54
Upside: -30.85%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $29.75
Upside: -79.83%